India Enforces Sweeping Crackdown on 90% of Inspected High-Risk Drug Facilities After Global Safety Crisis

NEW DELHI — India’s primary drug regulator has initiated enforcement actions against nearly 90% of pharmaceutical manufacturing facilities audited under a massive, nationwide safety sweep. The unprecedented regulatory crackdown, launched in late 2022 and extending into mid-2026, marks the most aggressive quality intervention in the history of the country’s multi-billion-dollar pharmaceutical sector.

The Central Drugs Standard Control Organisation (CDSCO), collaborating with state-level regulatory agencies, carried out more than 960 targeted audits since December 2022. Officials revealed that approximately 860 of these inspections uncovered critical non-compliance issues, resulting in punitive measures ranging from formal warning letters and manufacturing suspensions to total licence cancellations.

Unprecedented Regulatory Intervention

Speaking at the Global Drug Regulatory Conclave in New Delhi on July 30, 2026, Drugs Controller General of India (DCGI) Dr. Rajeev Raghuvanshi outlined the magnitude of the enforcement drive, emphasizing that the effort aims to protect global patient health while rebuilding trust in Indian-made medicines.

“We identify gaps, inform manufacturers, and give them time depending on the kind of issues and the severity of the impact on medicine quality,” Dr. Raghuvanshi explained.

The regulatory actions—which include Stop Production Orders (SPO), Stop Testing Orders (STO), and formal show-cause notices—are applied on a graduated scale based on the severity of risk posed to consumers.

Background: The Global Cough Syrup Crisis

This regulatory reckoning follows a series of international medical tragedies where Indian-manufactured pediatric cough syrups were linked to lethal toxicities overseas, triggering urgent alerts from the World Health Organization (WHO).

The contaminated products contained lethal concentrations of diethylene glycol (DEG) and ethylene glycol—industrial chemicals improperly substituted for non-toxic solvents like pharmaceutical-grade propylene glycol. These contaminants cause rapid acute kidney injury, which can swiftly prove fatal in young children without immediate, intensive intervention.

Key Tragedies Linked to Glycol Contamination:

• The Gambia (2022): 28 documented pediatric acute kidney injury deaths

• Uzbekistan (2023): 18 pediatric deaths

• Subsequent Outbreaks: Fatalities reported across Cameroon and other developing markets

Medical historians note that glycol contamination is an intermittent, persistent vulnerability in global drug supply chains. India experienced similar public health disasters in 1973, 1986, and 1998, which collectively claimed dozens of lives. The latest global crisis served as an urgent catalyst for structural regulatory reform.

Shift to a Risk-Based Inspection Model

Historically, drug inspections relied on routine schedules or localized complaints. The ongoing enforcement drive employs a Risk-Based Inspection (RBI) framework, aligning India’s regulatory apparatus with standards used by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Under this model, the CDSCO prioritizes facilities based on specific vulnerability metrics:

• Compliance History: Facilities with previous product recalls or drugs flagged as Not of Standard Quality (NSQ).

• Product Criticality: High-risk dosage forms, such as injectable vaccines, sterile ophthalmic solutions, and liquid pediatric syrups.

• Manufacturing Complexity: Processing units utilizing volatile organic solvents or complex chemical syntheses.

• Consumer and Adverse Event Reports: Facilities flagged by national or international health authorities.

• Audit Gaps: Sites that have lacked physical regulatory oversight for extended intervals.

       Risk-Based Inspection Framework
 ┌───────────────────────────────────────────┐
 │ Historical Non-Compliance (NSQ Records)   │
 │ High-Risk Product Formulations            │ ──► Priority Target
 │ Manufacturing Process Complexity           │     for Physical Audit
 │ International Adverse Event Flags         │
 └───────────────────────────────────────────┘

The Scale of the Supply Chain and Quality Oversight

Regulating India’s pharmaceutical ecosystem presents immense logistical challenges. The CDSCO oversees over 10,000 licensed manufacturing sites and an estimated one million retail pharmacies, operating within tight staffing parameters.

Data submitted to Parliament highlights the scope of ongoing quality monitoring across the domestic supply network:

While the percentage of substandard formulations remains under 4%, the absolute number of defective batches poses a global health concern. India supplies affordable generic drugs, vaccines, and active pharmaceutical ingredients (APIs) to more than 200 countries, earning its reputation as the “pharmacy of the world.”

Modernizing Regulation: AI and Revised Standards

To overcome personnel constraints, the CDSCO has digitized over 99% of its internal operations and is piloting artificial intelligence (AI) tools to enhance oversight capabilities.

The regulator’s new AI tools assist in:

1. Generating customized, site-specific pre-inspection checklists.

2. Assessing historical manufacturing data to recommend enforcement actions.

3. Classifying facility risk levels dynamically based on adverse event registries.

4. Accelerating the analysis of post-market surveillance reports.

Concurrently, regulators updated Schedule M of India’s Drugs and Cosmetics Rules, 1945, bringing domestic Good Manufacturing Practices (GMP) into full alignment with WHO international standards. Mandated compliance measures include overhauled environmental controls, validated water purification systems, strict equipment calibration, and rigorous safeguards against raw-material cross-contamination.

Industry Impact and Expert Perspectives

Public health advocates have welcomed the regulatory crackdown while emphasizing that long-term vigilance remains crucial.

“An enforcement rate near 90% among audited facilities demonstrates that regulators are serious, but the true test will be whether this translates into sustained improvements in medicine quality and patient safety on the ground,” noted a pharmaceutical policy researcher who was not involved in the government audits.

Representatives from the Indian Pharmaceutical Alliance (IPA) have acknowledged the necessity of tighter quality controls, while encouraging regulatory authorities to support smaller manufacturers attempting to meet updated GMP mandates.

Key Challenges Facing Full Implementation

• Resource Allocation: Overseeing 10,000+ facilities requires sustained financial and human resource expansion.

• Jurisdictional Uniformity: Harmonizing enforcement between the central CDSCO and individual state drug authorities remains an ongoing operational challenge.

• Financial Burden on Small Enterprises: Micro, small, and medium enterprises (MSMEs) face capital hurdles when upgrading physical plant infrastructure to meet revised Schedule M standards.

Practical Takeaways for Consumers and Patients

For patients globally who rely on generic medications, these regulatory measures offer several key assurances and practical updates:

• Greater Drug Safety: Systematic audits reduce the likelihood of contaminated or sub-potent medicines reaching pharmacies.

• Transparent Drug Alerts: Patients and healthcare providers can monitor monthly updates of substandard or fake batches directly via the CDSCO online portal (cdsco.gov.in).

• Potential Supply Shortages: Short-term localized drug shortages may occur as non-compliant facilities suspend operations to remediate their facilities.

Looking Ahead

As the CDSCO moves into subsequent phases of its risk-based inspection strategy through late 2026 and beyond, regulatory oversight is shifting permanently from reactive damage control to proactive, preventative oversight. The long-term success of this initiative will ultimately be judged by a reduction in adverse drug events, restored global trust, and safer clinical outcomes for millions of patients worldwide.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Reuters. “India takes action against 90% of inspected high-risk pharmaceutical facilities, regulator says.” Authors: Rishika Sadam and Kashish Tandon. Published July 30, 2026. Reuters Link